



MEKOPHAR

**CHEMICAL PHARMACEUTICAL
JOINT-STOCK COMPANY**

**CONSOLIDATED
FINANCIAL STATEMENTS**
Quarter 3 - 2017



CONSOLIDATED BALANCE SHEET

As at September 30, 2017

Unit : VND

ASSETS	Code	Notes	Sept. 30,2017	Jan. 01,2017
A - CURRENT ASSETS	100		842,826,645,808	923,454,144,991
I. Cash and cash equivalents	110	V.1	149,162,048,048	230,410,064,538
1. Cash	111		69,162,048,048	55,410,064,538
2. Cash equivalents	112		80,000,000,000	175,000,000,000
II. Short-term investments	120	V.2	30,946,711,100	170,946,711,100
1. Short-term investments	121		10,946,711,100	10,946,711,100
3. Held-to-maturity investments	123		20,000,000,000	160,000,000,000
III. Accounts receivable	130		394,151,382,748	300,907,917,287
1. Trade accounts receivable	131	V.3	134,163,504,274	150,269,075,026
2. Prepayments to suppliers	132	V.4	258,478,799,703	149,414,501,757
6. Other receivables	136	V.5	1,509,078,771	1,224,340,504
IV. Inventories	140		222,881,809,417	209,547,773,156
1. Inventories	141	V.6	222,881,809,417	209,547,773,156
2. Provision for decline in value of inventories	149		-	-
V. Other current assets	150		45,684,694,495	11,641,678,910
1. Short-term prepayments	151	V.11	1,442,882,004	1,287,896,570
2. Deductible VAT	152		43,514,992,892	9,587,129,097
3. Taxes and other receivables from the State Budget	153		726,819,599	766,653,243
B - LONG-TERM ASSETS	200		385,398,842,080	226,199,803,342
I. Long-term receivables	210		-	-
II. Fixed assets	220		62,813,628,779	70,598,001,405
1. Tangible fixed assets	221	V.7	55,312,143,444	63,159,849,405
- Cost	222		241,095,793,102	238,838,472,817
- Accumulated depreciation	223		(185,783,649,658)	(175,678,623,412)
2. Finance lease assets	224		-	-
3. Intangible fixed assets	227	V.8	7,501,485,335	7,438,152,000
- Cost	228		10,146,451,139	10,066,451,139
- Accumulated amortization	229		(2,644,965,804)	(2,628,299,139)
III. Investment Properties	230		-	-
IV. Long-term work in progress	240		269,024,524,843	98,111,567,308
1. Long-term work in progress	241		-	-
2. Construction in progress	242	V.9	269,024,524,843	98,111,567,308
V. Long-term investments	250	V.10	51,929,249,904	57,490,234,629
1. Investments in subsidiaries	251		-	-
2. Investments in associates, joint-ventures	252		28,418,749,904	33,979,734,629
3. Other long-term investments	253		23,510,500,000	23,510,500,000
VI. Other long-term assets	260		1,631,438,554	-
1. Long-term prepaid expenses	261	V.11	1,631,438,554	-
TOTAL ASSETS (270 = 100 + 200)	270		1,228,225,487,888	1,149,653,948,333

RESOURCES	Code	Notes	Sept. 30,2017	Jan. 01,2017
C - LIABILITIES	300		204,529,082,491	170,720,777,860
I. Current liabilities	310		126,275,953,001	102,348,100,994
1. Trade accounts payable	311	V.12	50,142,599,331	45,027,181,129
2. Advances from customers	312	V.13	13,718,630,173	9,276,664,445
3. Taxes and other payables to the State Budget	313	V.14	16,554,652,396	4,152,194,663
4. Payables to employees	314		12,997,666,301	13,980,991,904
9. Other payables	319	V.15	7,407,309,284	7,482,078,739
12. Bonus and welfare fund	322		25,455,095,516	22,428,990,114
II. Long-term liabilities	330		78,253,129,490	68,372,676,866
6. Unrealized revenue	336		48,253,129,490	38,372,676,866
12. Provision for long-term liabilities	342	V.16	30,000,000,000	30,000,000,000
D - OWNERS' EQUITY	400		1,023,696,405,397	978,933,170,473
I. Owners' equity	410	V.17	1,023,696,405,397	978,805,250,183
1. Share capital	411		194,208,130,000	194,208,130,000
- Share with voting rights	411a		194,208,130,000	194,208,130,000
- Preferred shares	411b		-	-
2. Share premium	412		295,058,504,458	295,058,504,458
5. Treasury shares	415		(14,487,151,158)	(14,487,151,158)
8. Investment and development fund	418		448,083,058,734	403,510,093,275
11. Undistributed earnings	421		100,833,863,363	100,515,673,608
-Undistributed earnings up to period year -end	421a		4,050,162,024	-
-Undistributed earnings this period	421b		96,783,701,339	100,515,673,608
12. Investment reserve for basic construction	422		-	-
II. Budget sources and other funds	430	V.18	-	127,920,290
1. Budget sources	431		-	127,920,290
2. Fund to form fixed assets	432		-	-
TOTAL RESOURCES (440 = 300 + 400)	440		1,228,225,487,888	1,149,653,948,333

Prepared By



Le Thi Thu Huong

Chief Accountant



Le Thi Thuy Hang

HC MC, November 21, 2017



General Director

Huynh Thi Lan

**MEKOPHAR Chemical Pharmaceutical Joint Stock Company**

Addr: 297/5 Ly Thuong Kiet st, Dist 11, Ho Chi Minh City, VietNam

Tel: [028] 38650 258 - 38650 363

Fax: [028] 38650 394

Email: info@mekophar.com

website: www.mekophar.com

Form B 02 - DN**CONSOLIDATED INCOME STATEMENT****The Nine - month period ended 30 September 2017***Unit : VND*

ITEMS	Code	Notes	Three-month period ended		Nine-month period ended	
			30/09/2017	30/09/2016	30/09/2017	30/09/2016
1. Sales	01	VI.1	327,311,863,257	302,099,986,829	988,769,063,634	921,731,875,802
2. Less sales deductions	02	VI.2	84,115,843	43,466,873	260,456,005	217,970,832
3. Net sales	10	VI.3	327,227,747,414	302,056,519,956	988,508,607,629	921,513,904,970
4. Cost of sales	11	VI.4	258,870,478,312	242,719,992,661	782,541,868,289	732,127,893,077
5. Gross profit	20		68,357,269,102	59,336,527,295	205,966,739,340	189,386,011,893
6. Financial income	21	VI.5	9,299,198,800	1,404,261,716	24,408,594,370	17,609,983,109
7. Financial expenses	22	VI.6	189,424,464	212,499,168	793,818,970	616,782,531
<i>In which: loan interest expenses</i>	23		-	-	-	-
Gain/losses from Joint venture, associated Company	24		9,908,749,904	-	9,908,749,904	-
9. Selling expenses	25	VI.7	19,352,735,029	15,964,698,501	52,041,909,499	44,967,411,061
10. General & administration expenses	26	VI.8	23,890,452,777	25,708,556,172	63,361,984,943	65,734,697,333
11. Operating profit	30		44,132,605,536	18,855,035,170	124,086,370,202	95,677,104,077
12. Other income	31	VI.9	289,742,600	76,443,412	848,717,668	216,221,211
13. Other expenses	32	VI.10	150,656,707	-	151,664,108	-
14. Other profit	40		139,085,893	76,443,412	697,053,560	216,221,211
15. Net accounting profit before tax	50		44,271,691,429	18,931,478,582	124,783,423,762	95,893,325,288
16. Corporate income tax - current	51	VI.11	11,897,375,957	7,976,456,189	27,999,722,423	23,489,532,271
17. Corporate income tax - deferred	52		-	-	-	-
18. Net profit after corporate income	60		32,374,315,472	10,955,022,393	96,783,701,339	72,403,793,017
19. Earnings per share	70				5,056	4,797
20. Diluted earnings per share	71				5,056	4,797

Prepared By

Le Thi Thu Huong

Chief Accountant

Le Thi Thuy Hang

HCMC, November 21, 2017

General Director

**Huynh Thi Lan**



CONSOLIDATED CASH FLOW STATEMENT

(Under indirect method)

The Nine - month period ended 30 September 2017

Unit : VND

ITEMS	Code	Notes	Nine-month period ended	
			30/09/2017	30/09/2016
1	2	3	4	5
I. CASH FLOWS FROM OPERATING ACTIVITIES				
1. Net profit before tax	01		124,783,423,762	95,893,325,288
2. Adjustments for :			(23,684,144,215)	(6,713,007,541)
- Depreciation and amortisation	02		10,263,490,763	10,673,270,296
- Gains/losses from investing activities	05		(33,947,634,978)	(17,386,277,837)
3. Profit from operating activities before changes in working capital	08		101,099,279,547	89,180,317,747
- Increase (-)/ decrease (+) in receivables	09		(126,939,495,612)	(119,304,938,820)
- Increase (-)/ decrease (+) in inventories	10		(13,334,036,261)	14,065,457,586
- Increase (+)/ decrease (-) in payables	11		17,631,255,804	4,702,890,646
- Increase (-)/ decrease (+) in prepaid expenses	12		(1,786,423,988)	(1,324,235,962)
- Corporate income tax paid	15		(15,155,778,998)	(17,260,319,523)
- Other receipts from operating activities	16		-	-
- Other payments for operating activities	17		(8,523,509,284)	(6,793,785,548)
Net cash inflows/(outflows) from operating activities	20		(47,008,708,792)	(36,734,613,874)
II. CASH FLOWS FROM INVESTING ACTIVITIES				
1. Purchases of fixed assets and other long-term assets	21		(173,392,075,672)	(10,767,107,028)
2. Proceeds from disposals of fixed assets and other long-term assets	22		27,272,727	-
3. Loans granted, purchases of debt instruments of other entities	23		(20,000,000,000)	(170,000,000,000)
Collection of loans, proceeds from sales of debt instruments of other				
4. entities	24		160,000,000,000	197,000,000,000
5. Investments in other entities	25		(200,000,000,000)	-
6. Proceeds from divestment in other entities	26		-	-
7. Dividends and interest received	27		24,011,612,347	17,386,277,837
Net cash inflows/(outflows) from investing activities	30		(209,353,190,598)	33,619,170,809
III. CASH FLOWS FROM FINANCING ACTIVITIES				
1. Proceeds from issue of shares and capital contribution	31		200,000,000,000	14,760,000,000
6. Dividends paid	36		(24,886,117,100)	(29,691,534,000)
Net cash inflows/(outflows) from financing activities	40		175,113,882,900	(14,931,534,000)
Net cash inflows/(outflows) (50 = 20+ 30 + 40)	50		(81,248,016,490)	(18,046,977,065)
Cash and cash equivalents at the beginning of the year	60		230,410,064,538	92,788,491,782
Effect of foreign exchange differences	61		-	-
Cash and cash equivalents at the end of the year (70 = 50+60+61)	70		149,162,048,048	74,741,514,717

Prepared By

Le Thi Thu Huong

Chief Accountant

Le Thi Thuy Hang

November 21, 2017

General Director



Huynh Thi Lan



NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

For the accounting period from Jan. 01, 2017 to Sept. 30, 2017

Unit: VND

I. BUSINESS HIGHLIGHTS

1. Establishment

Mekophar Chemical Pharmaceutical Joint-Stock Company, whose business code is 0302533156, operates under Business registration certificate No. 4103000833 dated February 08, 2002 issued by the Department of Planning and Investment of Ho Chi Minh City and The seventeenth amended certificate dated October 27, 2016, the chartered capital is VND 194.208.130.000.

English name: Mekophar Chemical Pharmaceutical Joint Stock Company

Short name: Mekophar

Head office: No. 297/5 Ly Thuong Kiet Str., Dist. 11, HCMC.

The Company's branches are located at:

Hanoi branch: No. 95 Lang Ha Str., Dong Da Dist., Hanoi City

Nghe An Branch: No. 11A4 Dang Thai Than, Cua Nam Ward, Vinh City, Nghe An Province

Da Nang branch: No. 410 Nguyen Tri Phuong, Hai Chau District, Da Nang City

Can Tho branch: No.17A Cach Mang Thang Tam Str., Binh Thuy Dist., Can Tho City

2. Structure of ownership:

Joint Stock Company.

3. Business sector:

Production and trading.

4. Principal activities

The Company's principal activities: Producing, trading medicine; Trading perfume; ; Trading cosmetics and other cleaning products; Trading medical tools; Maintaining and testing medicine; Retailing medicine; Producing packing used in pharmaceutical industry (plastic bottle, paper box, carton box); Producing technological food (except for producing and processing fresh food); Trading functional food; processing food; Producing cosmetics (not manufacturing chemicals, soap, and detergent at the head office); Trading real estates, leasing apartment, office; Trading garments; Producing bottled pure water; Trading beverages; Trading medical machinery and equipment; Trading other chemicals (except for chemicals used in agriculture); Trading plastics in primary form; Investment consultancy (except for accounting, finance, law); Consultancy on technology transfer; Commercial introduction and promotion; Acting as brokerage agent (except for real estates).

5. Normal operating cycle

Normal operating cycle of the Company lasts 12 months of the normal fiscal year beginning from January 01 and ending on December 31.

6. Operations in the fiscal year affecting the financial statements: Not applicable.

7. Total employees to September 30, 2017: 768 persons.

8. Enterprise Structure

8.1. List of subsidiaries

As at September 30, 2017, the Company has one (01) directly owned company as follows:

Company's name and address	Principal activities	Percentage of shareholding	Percentage of owning	Percentage of voting right
Mekophar Co.,Ltd Head office: Lot I-9-5, D2 Street, High-Tech Park, Long Thanh My Ward, District 9, HCMC	Producing biological products, medicine, cosmetics, functioning food ...and original cell	100%	100%	100%

8.2. List of Joint-ventures and associates

As at September 30, 2017, the Company has one (01) associate as follows:

Company's name and address	Principal activities	Percentage of shareholding	Percentage of owning	Percentage of voting right
An Sinh Hospital 10 Tran Huy Lieu, Ward 12, Phu Nhuan, HCMC	Medically examining and treating	22%	22%	22%

II. ACCOUNTING PERIOD AND REPORTING CURRENCY

1. Fiscal year

The fiscal year is begun on January 01 and ended December 31 annually.

2. Reporting currency

Vietnam Dong (VND) is used as a currency unit for accounting records.

III. ADOPTION OF ACCOUNTING STANDARDS AND POLICIES

1. Applicable Accounting System

The Company applies Vietnamese Corporate Accounting System issued by the Vietnam Ministry of Finance in accordance with the guidance of Circular No. 200/2014/TT-BTC dated December 22, 2014.

2. Disclosure of compliance with Vietnamese Accounting Standards and the Vietnamese Accounting

We conducted our accounting, preparation and presentation of the financial statements in accordance with Vietnamese Accounting Standards and other relevant statutory regulations. The financial statements give a true and fair view of the state of affairs of the Company and the results of its operations as well as its cash flows.

The selection of figures and information presented in the notes to the financial statements is complied with the material principles in Vietnamese Accounting Standard No.21 - Presentation of the financial statements.

IV. APPLICABLE ACCOUNTING POLICIES

1. Foreign exchange rate applicable in accounting

The Company has translated foreign currencies into Vietnam Dong at the actual rate and book rate.

Principles for determining the actual rate

All transactions denominated in foreign currencies which arise during the period (trading foreign currencies, capital contribution or receipt of contributed capital, recording receivables and payables, purchasing assets or costs immediately paid by foreign currencies) are converted at the actual exchange rates ruling as of the transaction dates.

Closing balance of monetary items (cash, cash equivalents, payables and receivables, except for prepayments to suppliers, prepayments from customers, pre-paid expenses, deposits and unearned revenue) denominated in foreign currencies should be revaluated at the actual rate ruling as of the balance sheet date.

- The actual exchange rates upon revaluation of monetary assets denominated in foreign currencies which have been classified as assets will be the buying rate of Vietcombank. The buying rate as at September 30, 2017: 22,690VND/USD; 26,646 VND/EUR.

- The actual exchange rates upon revaluation of monetary assets denominated in foreign currencies which have been classified as payables will be the selling rate stated by Vietcombank. The exchange rate as at September 30, 2017: 22,765 VND/USD; 26,922 VND/EUR.

Foreign exchange differences, which arise from foreign currency transactions during the period/year, shall be included in the income statement. Foreign exchange differences due to the revaluation of ending balances of the monetary items in foreign currencies after offsetting their positive differences against negative differences shall be included in the income statement.

Principle for determining book rate

When recovering receivables, deposits or payments for payables in foreign currencies, the Company uses specific identification book rate.

When making payment by foreign currencies, the Company uses moving weighted average rate.

2. Principles for recording cash and cash equivalents

Cash includes cash on hand, demand deposit and cash in transit.

Cash equivalents comprise term deposits and other short-term investments with an original maturity of three months or less, highly liquid, readily convertible to known amount of cash and subject to an insignificant risk of changes in value.

3. Principles for accounting financial investments

Principles for accounting held-to-maturity investments

Held-to-maturity investments include term deposits (including treasury bill, bill of exchange), bonds, loans, preferred share that the issuer is required to re-buy them in a certain time in the future and held-to-maturity loans for the purpose of periodic interest receiving and other held-to-maturity investments.

The held-to-maturity investments are initially recorded at the original cost including buying price and costs attributable to the acquisition of the investments. After initial recognition, if the provision for doubtful debts has not been made as statutorily required, these investments are revaluated at the recoverable value. When firm evidence shows that a portion or the whole investments may be unrecoverable, the loss will be recorded in financial expenses in the year and recorded in decrease of the investment's value.

Principles for recording financial investments in Subsidiary, Joint-ventures, Associates

Principles for recording financial investments in subsidiaries: Subsidiary is a company which the Company has shareholding of more than one half of the voting right in order to govern the financial and operating policies in order to obtain economic benefits from the subsidiary's operation. When the Company ceases to control the subsidiary, the investment in the subsidiary will be written down.

The investment in Joint-ventures is recorded when the Company holds joint control over these entities' financial and operating policies. When the Company ceases to control these entities, the investment will be written down.

The investment in associate is recorded when the Company has 20% - 50% of voting right in those companies and has considerable influence over their decisions on financial policies.

Investments in Subsidiary, Joint-ventures, associates are initially stated at original cost and will not be adjusted thereafter for change in the investor's share of the investee's net assets. The original cost includes purchase price and costs attributable to the investment. In case the investment is by non-monetary assets, the investment fee should be recorded at the fair value of the non-monetary assets at the date of occurrence.

Provision for loss of investments in subsidiaries, joint-ventures, associates is made when the investee suffers from loss and thus the Company possibly loses its capital or the investments' value is devalued. Basis for making provision for loss of investments is consolidated financial statements of the investee (if it is parent company), the investee's financial statements (if it is an independent enterprise without subsidiary).

Principles for recording equity investments in other entities

Equity investment in other entities represents the Company's investment in other entities' equity instruments. However, the Company does not hold any control or joint control right and exercise significant influences over the investees either.

The investments are stated at original cost including purchase price and costs directly attributable to the investment. In case of non-monetary assets investment, the investment fee should be recorded at the fair value of the non-monetary assets at the date of occurrence.

Regarding the investments the Company holds in a long time (not trading securities) and no significant influences are exercised on the investees, provision for loss will be made as follows:

- + If an investment in listed shares or the fair value of the investment is determined reliably, the allowance shall be made according to the market values of the shares.
- + If it is impossible to determine the investments' fair value at the reporting date, the provision will be made on the basis the loss that investee suffers. Basis for making provision for loss of investments is consolidated financial statements of the investee (if it is parent company), the investee's financial statements (if it is an independent enterprise without subsidiary).

4. Principles for recording trade receivables and other receivables:

Principle for recording receivables: At original cost less provision for doubtful debts.

The classifying of the receivables as trade receivables, inter-company receivables and other receivables depends on the nature of the transaction or relationship between the company and debtor.

Method of making provision for doubtful debts: Provision for doubtful debts is estimated for the loss value of the receivables, other held-to-maturity investments similar to doubtful debts that are overdue and undue, but are likely to become possibly irrecoverable due to insolvency of debtors who go bankruptcy, making procedures for dissolution, go missing or run away....

5. Principles for recording inventories:

Principles adopted in recording inventory: Inventories are stated at original cost less (-) the provision for the decline in value of obsolete and deteriorated inventories.

Original costs are determined as follows:

- The original cost of materials, merchandises consists of costs of purchase, costs of transportation and other costs incurred in bringing the inventories to their present location and condition.
- Finished goods: costs of materials, direct labor and manufacturing overheads which are allocated on the basis of major materials costs/normal operation level/costs of land use right and relevant overall costs incurred in the duration of building properties.
- Work in progress: costs of raw materials, labor and other directly costs for producing inventories incurred in the duration of building works in progress...

Method of calculating inventories' value: Weighted average method.

Method of accounting for the inventories: Perpetual method.

Method of making provision for decline in value of inventories: Provision for decline in value of inventories is made when the net realisable value of inventories is lower than their original cost. Net realisable value is the estimated selling price less the estimated costs of completion and selling expenses. Provision for decline in value of inventories is the difference between the cost of inventories greater than their net realisable value. Provision for decline in value of inventories is made for each inventory with the cost greater than the net realisable value.

6. Principles for recording fixed assets:

6.1 Principles for recording tangible fixed assets:

Tangible fixed assets are stated at original cost less accumulated depreciation. The initial cost of a tangible fixed asset comprises all expenditures of bringing the asset to its working condition and location for its intended use. The expenditures incurred beyond their originally assessed standard of performance are capitalised as an additional cost of tangible fixed assets when they have resulted in an increase in the future economic benefits expected to be obtained from the use of those tangible fixed assets. The expenditures which do not meet the above conditions are charged to the expenses in the year.

When the assets are sold or disposed, their original costs and the accumulated depreciation which have been written off and any gain or loss from disposal of assets are recorded in the income statement.

Determination of original costs of tangible fixed assets:

Tangible fixed assets purchased

The original cost of purchased tangible fixed assets shall consist of the actual purchase price less (-) trade discounts or reduction plus (+) taxes (excluding taxes to be refunded) and relevant expenses calculated to the time when such fixed assets are put into operation such as fees for installation and trial operation of fixed assets; specialists and other direct costs.

The original cost of a tangible fixed asset formed from capital construction under the mode of tendering shall be the finalisation price of the construction project, other relevant fees plus (+) registration fee (if any).

Fixed assets which are buildings, structures attached to land use right, the value of land use right is computed separately and recorded as intangible fixed assets.

6.2 Principles for recording intangible fixed assets:

Intangible fixed assets are stated at cost less accumulated amortization. The original cost of a intangible fixed asset comprises all costs of owning the asset to the date it is put into operation as expected.

Principles for recording intangible fixed assets:

Purchase of separate intangible fixed assets

The original cost of purchased intangible fixed assets shall consist of the actual purchase price payable less (-) trade discounts or reduction plus (+) taxes (excluding taxes to be refunded) and relevant expenses calculated to the time when such fixed assets are put into operation. The land use rights which are purchased together with buildings, structures will be determined separately and recorded as intangible fixed assets.

If an intangible fixed asset is formed from the exchange involving payment accompanied with vouchers related to the capital ownership of the establishment, its original cost is the reasonable value of vouchers issued in relation to capital ownership.

Land use right

The original cost of an intangible fixed asset which is the land use right shall be the payment made to obtain the lawful land use right plus (+) compensatory payments for clearance of site, expenses for

Computer software

The original cost of a in tangible fixed asset which is the computer software shall be the total of actual expenses incurred by the Company to obtain the computer software.

6.3 Method of depreciating and amortizing fixed assets

Depreciation is charged to write off the cost of fixed assets on a straight line basis over their estimated useful lives. Useful life means the duration in which the tangible fixed assets produce their effect on production and business.

The estimated useful life for assets is as follows:

<i>Buildings and structures</i>	<i>5 - 25 years</i>
<i>Machinery and equipment</i>	<i>3 - 12 years</i>
<i>Transportation and facilities</i>	<i>5 - 8 years</i>
<i>Office equipment</i>	<i>3 - 10 years</i>
<i>Right to use original cells</i>	<i>3 years</i>
<i>Land use rights indefinitely recorded at cost and is not amortized .</i>	

7. Principles for recording construction in progress:

Construction in progress is stated at original cost. These are all necessary costs for purchasing fixed assets.

These costs are capitalised as an additional cost of asset when the works have been completed. After the works have been finalized, the asset will be handed over and put into use.

8. Principles for recording liabilities

Liabilities are recorded at original cost and not lower than the payment obligation.

Liabilities shall be classified into trade payables, inter-company payables and other payables depending on the nature of transactions and relationship between the Company and debtors.

Liabilities must be kept records in detail according to payment schedule, creditor, type of original currency (including revaluation of liabilities payable which satisfying the definition of monetary assets denominated in foreign currencies) and other factors according to requirements of the enterprise.

At the reporting date, if it is evident that there is an unavoidable loss, an amount payable shall be recorded according to cautious rules.

9. Principles for recording provision liabilities:

Provisions are recognized when the following conditions are satisfied: the Company has a present (legal or constructive) obligations as a result of past events; it is probable that an outflow of resources will be required to settle the obligation and the amount has been reliably estimated.

Value of provision liability being recorded: The value which is estimated to be the most reasonable for settling the present obligation at the balance sheet date.

Provision for payables includes the expenditures for doing scientific research. The provision value depends on the Company's operating results of each year.

10. Principles for recoding unearned revenue

Unrealized revenue is the amount the customers prepaid for one or several accounting periods

Unearned revenue include amounts of customers paid in advance for one or many accounting periods for the revenue in correspondence with the value of goods, services.

Method of allocating unearned revenue is on the principle of conformity with obligations that the Company will perform in next one or several accounting periods.

11. Principles for recording owner's Equity

Principles for recording owner's Equity

The owners' equity is the amount that is contributed by members and supplemented from the profit after tax. The owners' equity will be recorded at the actual contributed capital by cash or assets in the early establishment period or additional mobilization to expand operation.

Principles for recording share premium, convertible bond option and other capitals

+ **Share premium** is the difference between the cost over and above the nominal value of the first issued or additionally issued share and the differences (increase or decrease) of the actual receiving amount against the repurchase price when treasury share is reissued. In case where shares are repurchased to cancel immediately at the purchase date, shares' value recorded decrease the business capital source at purchase date is the actual repurchase price and the business resource should be written down according to the par value and share premium of the repurchased shares.

+ Principles for recognising undistributed profit:

The undistributed profit is recorded at the profit (loss) from the Company's result of operation after deducting the current year corporate income tax and the adjusted items due to the retroactive application of changes in accounting policy and adjustments for material misstatement of the previous year.

The distributing of profit is based on the charter of the Company approved by the annual shareholder meeting.

12. Principles for recording treasury shares

The owners' equity instruments acquired by the Company (treasury share) are recorded at original cost and deducted into the owners' equity. The Company does not record gain (loss) when purchasing, selling, issuing or cancelling its equity instruments.

13. Principles for recording revenues

Revenue from goods sold

Revenue from the sale of good should be recognised when all the five (5) following conditions have been satisfied: 1) The enterprise has transferred to buyer the significant risks and rewards of ownership of the goods; 2) The enterprise retains neither continuing managerial involvement as an owner nor effective control over the goods sold; 3) The amount of revenue can be measured reliably; When the contract specifies that buyers are entitled to return products, goods they have bought under specific conditions, the enterprise will record the revenue only when those conditions no longer exist and the buyers do not have right to return products, goods (except for changing to other goods, services) 4) The economic benefits associated with the transaction has flown or will flow to the enterprise; 5) The costs incurred or to be incurred in respect of the transaction can be measured reliably.

Revenue from service rendered

Revenue from services rendered is recorded when the result of the supply of services is determined reliably. In case where the services are rendered in several periods, the revenue will recorded by the part of completed works at the balance sheet. Revenue from services rendered is determined when the following four conditions have been satisfied: 1. The revenue is determined firmly; When the contract specifies that buyers are entitled to return the service they have bought under specific conditions, the enterprise will record the revenue only when those conditions no longer exist and the buyers do not have right to return service; 2. The economic benefits associated with the transaction has flown or will flow from the supply of the provided service; 3. Part of completed works can be determined at the balance sheet date; 4. The costs incurred or to be incurred in respect of the transaction can be measured reliably.

If the contract's results can not be determined firmly, the revenue will be recorded at the recoverable level of expenses recorded.

Principles and method of recording revenue from asset lease

Revenue from asset lease is recorded on the principle of allocating advanced lease amount in conformity with lease term.

Principles for recording financial income

Financial incomes include interests, royalties, distributed dividends and profits and income from other financing activities (sale and purchase of securities, liquidation of capital in joint-ventures, investment in associates, subsidiaries, other investments; Foreign exchange gains).

Income arising from interests, royalties, distributed dividends and profits of the enterprises shall be recognized if they simultaneously satisfy the two (2) conditions below 1. It is possible to obtain economic benefits from the concerned transactions; 2. Income is determined with relative certainty.

- Interests recognized on the basis of the actual time and interest rates in each period;
- Royalties recognized on the basis of accrualment in compliance with the contracts;

- Distributed dividends and profits shall be recognized when shareholders are entitled to receive dividends or the capital-contributing parties are entitled to receive profits from the capital contribution.

When an amount which has been recorded as an income becomes irrecoverable, such irrecoverable or uncertainly recoverable amount must be accounted as expense incurred in the period, but not recorded as income decrease.

14. Principles and method of recording cost of goods sold

Cost of goods sold are the cost of products, goods, services, investment properties; cost of construction products (as to construction enterprise) sold in the period; expenses related to trading the investment properties and other expenses recorded in the cost of goods sold or recorded a decrease in the cost of goods sold in reporting period. The cost of goods sold is recorded at the date the transaction incurs or likely to incur in the future regardless payment has been made or not. The cost of goods sold and revenue shall be recorded simultaneously on conformity principles. Expenses exceeding normal consumption level are recorded immediately to the cost of goods sold on prudent principle.

15. Principles and method of recording financial expenses

Financial expenses include expenses or loss related to the financial investment, borrowing cost and capital borrowing, contribution in joint-venture, associate, provision for devaluation of financial investment, loss from sale of foreign currencies, loss from foreign exchange loss and other financial

Financial expenses are recorded in details by their content and determined reliably when there are sufficient evidences on these expenses.

16. Principles and methods of recording current taxes and deferred taxes

Corporate income tax includes current corporate income tax and deferred corporate income tax incurred in the year and set basis for determining operating result after tax in current fiscal year.

Current tax: is the tax payable on the taxable income and tax rate enacted in current year in accordance with the law on corporate income tax.

The tax amounts payable to the State budget will be finalized with the tax office. Differences between the tax amounts payable specified in the book and the tax amounts under finalization will be adjusted when the tax finalization has been issued by the tax office.

Tax policies the Company should comply with are as follows:

The Company pays tax at 20%.

17. Principles for recording earnings per share

Basic earnings per share is calculated by dividing net income available to common shareholders before appropriating to Bonus and Welfare Fund by the weighted-average number of common shares outstanding during the period.

Diluted EPS is calculated by dividing net income available to common shareholders (after adjusting dividends of preferred convertible shares) by the weighted-average number of common share outstanding and the weighted-average number to be issued in case where all dilutive potential common are converted into common shares.

18. Financial instruments:

Initial recognition

Financial assets

According to Circular No. 210/2009/TT-BTC dated November 06, 2009 (Circular No. 210), financial assets are classified properly, for the purpose of presentation in the financial statements, into the financial assets which are stated at fair value through the Income Statement, loans and receivables, held-to-maturity investments and available-for-sale financial assets. The Company decides to classify these assets at the date of initial recognition.

At the date of initial recognition, the financial assets are recognized at cost plus transaction cost that are directly attributable to the acquisition of the financial assets.

Financial assets of the Company comprise cash, short-term deposits, trade accounts receivables and other receivables.

Financial liabilities

According to Circular 210, financial assets are classified properly, for the purpose of presentation in the financial statements, into the financial liabilities which are stated at fair value through the Income Statement, financial liabilities determined on amortised cost basis. The Company decides to classify these liabilities at the date of initial recognition.

At the date of initial recognition, the financial liabilities are recognized at cost plus transaction cost that are directly attributable to the acquisition of the financial liabilities.

Financial liabilities of the Company comprise trade payables, other payables, borrowings and liabilities.

Re-measurements after initial recognition

Currently, there are no requirements for the re-measurement of the financial instruments after initial recognition.

Offsetting

Financial assets and financial liabilities are offset and the net amount reported in the report on financial position if, and only if, there is a currently enforceable legal right to offset the financial assets against financial liabilities or vice-versa and there is an intention to settle on a net basis or to realize the assets and settle the liability simultaneously.

19. Related parties

Related parties include: Enterprises and individuals that directly, or indirectly through one or more intermediaries, control, or are controlled by, or are under common control with the Company. Associates and individuals owning, directly or indirectly, an interest in the voting power of the Company that gives them significant influence over the enterprise, key management personnel, including directors and officers of the Company and close members of the family of these individuals and companies associated with these individuals also constitute related parties. In considering each possible related party relationship, attention is directed to the substance of the relationship, and not merely the legal form.

20. Principles for presenting assets, revenue and operating results by segment

A reportable segment includes business segment or a geographical segment.

A business segment is a distinguishable component of an enterprise that is engaged in providing an individual product or service or a group of related products or services and that is subject to risks and returns that are different from those of other business segments.

A geographical segment is a distinguishable component of an enterprise that is engaged in providing products or services within a particular economic environment and that is subject to risks and returns that are different from those of components operating in other economic environments.

For the purpose of management, the Company operates in a large scale of the country, so it presents major segment reporting by business sector, the minor segment reporting by geographical segment.

V. ADDITIONAL INFORMATION FOR ITEMS SHOWN IN THE BALANCE SHEET

1. Cash and cash equivalents	Sept. 30, 2017	Jan. 01, 2017
Cash	69,162,048,048	55,410,064,538
Cash on hand	2,347,447,243	5,732,245,701
Demand deposits	66,814,600,805	49,677,818,837
VND	63,173,990,220	49,053,800,148
USD	3,640,610,585	624,018,689
Cash Equivalents	80,000,000,000	175,000,000,000
Total	149,162,048,048	230,410,064,538

2. Short-term financial investments

	Sept. 30, 2017		Jan. 01, 2017	
	Amount	Value	Amount	Value
Trading securities	676,956	10,946,711,100	676,956	10,946,711,100
<i>VIDIPHAR Pharmaceutical JSC</i>	<i>180,000</i>	<i>4,070,000,000</i>	<i>180,000</i>	<i>4,070,000,000</i>
<i>Pharmaceutical Packaging JSC</i>	<i>477,775</i>	<i>6,635,250,000</i>	<i>477,775</i>	<i>6,635,250,000</i>
<i>OPC Pharmaceutical JSC</i>	<i>19,181</i>	<i>241,461,100</i>	<i>19,181</i>	<i>241,461,100</i>
Held-to-maturity investments		20,000,000,000		160,000,000,000
<i>Term deposits</i>		<i>20,000,000,000</i>		<i>160,000,000,000</i>
Total		30,946,711,100		170,946,711,100

3. Trade accounts receivable	Sept. 30, 2017	Jan. 01, 2017
Local customers	98,740,430,689	103,701,894,371
Foreign customers	35,423,073,585	46,567,180,655
Total	134,163,504,274	150,269,075,026

4. Prepayments to suppliers	Sept. 30, 2017	Jan. 01, 2017
Local customers	96,264,769,628	100,747,663,401
Foreign customers	162,214,030,075	48,666,838,356
Total	258,478,799,703	149,414,501,757

5. Other receivables	Sept. 30, 2017	Jan. 01, 2017
Short-term		
Advances	778,002,804	29,108,305
<i>Health, social insurance, trade union fee</i>	529,325,967	829,271,199
<i>Consideration for the members of the Board of Management not holding direct management</i>	192,000,000	330,000,000
<i>Other receivables</i>	9,750,000	35,961,000
Total	1,509,078,771	1,224,340,504

6. Inventories	Sept. 30, 2017	Jan. 01, 2017
Raw materials	132,069,917,393	133,722,533,959
Tools & supplies	2,541,056,342	1,839,884,708
Works in progress	19,857,268,883	18,428,015,539
Finished goods	68,385,977,467	55,346,644,104
Merchandise inventory	27,589,332	210,694,846
Total	222,881,809,417	209,547,773,156

7. Tangible fixed assets (See page 20)

8. Intangible fixed assets

	Land use rights	Patents, copyrights	Total
Original cost			
Opening balance	7,438,152,000	2,628,299,139	10,066,451,139
<i>New purchases</i>		<i>80,000,000</i>	<i>80,000,000</i>
<i>Disposal, sale</i>			
Closing balance	7,438,152,000	2,708,299,139	10,146,451,139
Accumulated amortization			
Opening balance	-	2,628,299,139	2,628,299,139
<i>Charge for the year</i>		<i>16,666,665</i>	<i>16,666,665</i>
<i>Disposal, sale</i>			
Closing balance	-	2,644,965,804	2,644,965,804
Net book value			
As at the beginning of the period	7,438,152,000	-	7,438,152,000
As at the end of the period	7,438,152,000	63,333,335	7,501,485,335

9. Capital construction in progress	Sept. 30, 2017	Jan. 01, 2017
Accounting software	2,825,577,000	2,685,477,000
Purchase fixed assets	4,077,954,390	-
Project of Investing in Development Research and Producing Biological and Pharmaticeual Products.	262,120,993,453	95,426,090,308
Total	269,024,524,843	98,111,567,308

10. Long-term investments

	Sept. 30, 2017		Jan. 01, 2017	
	Amount	Value	Amount	Value
Investments in associates, joint-ventures	2,464,000	33,979,734,629	2,464,000	33,979,734,629
An Sinh Hospital - Percentage of contribution: 22%	2,464,000	33,979,734,629	2,464,000	33,979,734,629
Investments in equity of other entities	-	23,510,500,000	-	23,510,500,000
Orchids Co.,Ltd - Percentage of contribution: 15%		5,550,000,000		5,550,000,000
ARECO Real Estates Co.,Ltd - Percentage of contribution: 5%		17,960,500,000		17,960,500,000
Total	2,464,000	57,490,234,629	2,464,000	57,490,234,629

On September 30, 2017 the Company used the amount of VND 600.000.000.000 to invest in Mekophar Co.,Ltd for building new plant of the Project "Investing in Development research and producing biological and Pharmaticeual Products " of Mekophar Co.,Ltd, High -Tech Zone, Long Thanh My Ward, Dist. 9, HCMC.

11. Prepaid expenses	Sept. 30, 2017	Jan. 01, 2017
Short-term prepaid expenses		
Expenses of giving consultancy for Kinh Duong Vuong Project	90,000,000	90,000,000
Office lease in Nghe An Branch	96,000,000	-
Fire insurance costs	424,029,416	-
Repair of fixed assets	524,203,338	1,180,846,572
Other expenses (Mekophar Co.,Ltd.)	308,649,250	17,049,998
Total	1,442,882,004	1,287,896,570
Long-term prepaid expenses		
Repair of fixed assets	1,397,670,554	-
Other expenses (Mekophar Co.,Ltd.)	233,768,000	-
Total	1,631,438,554	-
12. Trade payables	Sept. 30, 2017	Jan. 01, 2017
Local suppliers	43,523,022,557	41,220,845,923
Foreign suppliers	5,310,519,350	3,806,335,206
Total	48,833,541,907	45,027,181,129
13. Prepayments from customers	Sept. 30, 2017	Jan. 01, 2017
Local customers	9,520,433,820	9,148,136,818
Foreign customers	4,198,196,353	128,527,627
Total	13,718,630,173	9,276,664,445
14. Taxes and payables to the State Budget	Sept. 30, 2017	Jan. 01, 2017
VAT ouput	79,582,022	999,090,217
VAT on import	-	84,522,363
Personal income tax	15,912,525,508	3,068,582,083
Land and housing taxes, land rentals	562,544,866	-
Total	16,554,652,396	4,152,194,663
15 Short-term other payables	Sept. 30, 2017	Jan. 01, 2017
Social insurance, health insurance, trade union fee, Communist party membership fee	263,964,706	143,389,092
Costs of Mekostem project	-	177,595,069
Board of Management	23,000,000	46,000,000
Other payables	7,120,344,578	7,115,094,578
Total	7,407,309,284	7,482,078,739
16. Long-term provision liability	Sept. 30, 2017	Jan. 01, 2017
Provision for research projects	30,000,000,000	30,000,000,000
Total	30,000,000,000	30,000,000,000

17. Owners' equity**a. Comparison schedule for changes in Owner's Equity (See page 21)****b. Details of owners' shareholding**

	% of shareholding	Sept. 30, 2017	Jan. 01, 2017
Shareholding by the State	18.2%	35,283,600,000	35,283,600,000
Shareholding by other investors	81.8%	158,924,530,000	158,924,530,000
Share premium		295,058,504,458	295,058,504,458
Treasury share		(14,487,151,158)	(14,487,151,158)
Total	100.0%	474,779,483,300	474,779,483,300

* Number of treasury shares: 277.646, equivalent to VND14.487.151.158.

c. Shares

	Sept. 30, 2017	Jan. 01, 2017
Number of shares registered to be issued	19,420,813	19,420,813
Number of shares sold out to the public	19,420,813	19,420,813
<i>Ordinary share</i>	<i>19,420,813</i>	<i>19,420,813</i>
Number of shares repurchased	277,646	277,646
<i>Ordinary share</i>	<i>277,646</i>	<i>277,646</i>
Number of existing shares in issue	19,143,167	19,143,167
<i>Ordinary share</i>	<i>19,143,167</i>	<i>19,143,167</i>
<i>Par value: VND/share.</i>	<i>10,000</i>	<i>10,000</i>

18. Source for non-business expenditures

	Sept. 30, 2017	Jan. 01, 2017
Source for non-business expenditures	-	127,920,290
Total	-	127,920,290

VI. ADDITIONAL INFORMATION FOR ITEMS IN THE INCOME STATEMENT**1. Sales**

	From Jan. 01, 2017 to Sept. 30, 2017	From Jan. 01, 2016 to Sept. 30, 2016
Revenue from finished goods sold	487,941,461,098	467,581,032,989
Revenue from services of original cells bank	36,557,202,870	39,567,843,976
Revenue from merchandises sold	451,562,892,524	405,100,415,454
Revenue from sale of materials	7,378,416,234	7,017,128,837
Revenue from office lease	5,329,090,908	2,465,454,546
Total	988,769,063,634	921,731,875,802

2. Sales deductions

	From Jan. 01, 2017 to Sept. 30, 2017	From Jan. 01, 2016 to Sept. 30, 2016
Sales returns	215,496,005	217,970,832
Discount sales	44,960,000	
Total	260,456,005	217,970,832

3. Net sales

	From Jan. 01, 2017 to Sept. 30, 2017	From Jan. 01, 2016 to Sept. 30, 2016
Revenue from finished goods sold	487,732,763,407	467,363,062,157
Revenue from exchange of services	36,512,242,870	39,567,843,976
Revenue from merchandises sold	451,556,094,210	405,100,415,454
Revenue from construction contract	7,378,416,234	7,017,128,837
Revenue from trading investment properties	5,329,090,908	2,465,454,546
Total	988,508,607,629	921,513,904,970

4. Cost of sales

	From Jan. 01, 2017 to Sept. 30, 2017	From Jan. 01, 2016 to Sept. 30, 2016
Cost of finished goods sold	317,883,124,175	318,142,844,827
Cost of service of original cells bank	10,659,201,683	7,002,401,010
Cost of merchandises sold	448,692,359,449	402,125,486,836
Cost of materials, services rendered	5,307,182,982	4,857,160,404
Total	782,541,868,289	732,127,893,077

	From Jan. 01, 2017 to Sept. 30, 2017	From Jan. 01, 2016 to Sept. 30, 2016
5. Financial income		
Interest income from deposits, loans	14,039,795,171	12,609,918,837
Dividends, profit paid	9,971,817,176	4,776,359,000
<i>Mekong Pharmaceutical JSC</i>	-	50,000,000
<i>An Sinh General Hospital Co., Ltd</i>	9,592,658,176	4,000,000,000
<i>VIDIPHAR Pharmaceutical JSC</i>	359,978,000	179,978,000
<i>Pharmaceutical Packaging Joint Stock Company</i>	-	527,200,000
<i>OPC Pharmaceutical Joint Stock Company</i>	19,181,000	19,181,000
Realised foreign exchange gains	396,982,023	223,705,272
Total	24,408,594,370	17,609,983,109
	From Jan. 01, 2017 to Sept. 30, 2017	From Jan. 01, 2016 to Sept. 30, 2016
6. Financial expenses		
Realised foreign exchange losses	793,818,970	616,782,531
Total	793,818,970	616,782,531
	From Jan. 01, 2017 to Sept. 30, 2017	From Jan. 01, 2016 to Sept. 30, 2016
7. Selling expenses		
Salaries	19,004,797,591	16,506,781,701
Commission	14,389,202,728	12,171,617,527
Depreciation	402,955,965	471,153,581
Services bought from outsiders	13,106,090,161	11,770,857,709
Transportation	4,719,413,827	3,605,097,270
Other sundry expenses by cash	419,449,227	441,903,273
Total	52,041,909,499	44,967,411,061
	From Jan. 01, 2017 to Sept. 30, 2017	From Jan. 01, 2016 to Sept. 30, 2016
8. General and administration expenses		
Salaries	27,354,074,982	23,972,620,949
Materials and packaging	5,558,178,993	5,746,694,118
Depreciation	3,066,478,100	3,295,490,512
Taxes, fees and duties	8,776,185,968	12,907,952,891
Services bought from outsiders	2,139,335,026	2,018,710,693
Other sundry expenses by cash	16,467,731,874	17,793,228,170
Total	63,361,984,943	65,734,697,333
	From Jan. 01, 2017 to Sept. 30, 2017	From Jan. 01, 2016 to Sept. 30, 2016
9. Other income		
Liquidation of fixed assets	27,272,727	-
Other income (Treatment to surplus amount upon the counting	486,929,582	214,855,686
Other income	334,515,359	1,365,525
Total	848,717,668	216,221,211
	From Jan. 01, 2017 to Sept. 30, 2017	From Jan. 01, 2016 to Sept. 30, 2016
10. Other expenses		
Other expenses (Treatment to deficient amount upon the counting, other)	151,664,108	-
Total	151,664,108	-

	From Jan. 01, 2017 to Sept. 30, 2017	From Jan. 01, 2016 to Sept. 30, 2016
11. Current corporate income tax		
- Total accounting profit before tax	124,783,423,762	95,893,325,288
- Adjustments to increase accounting profit to determine taxable income	24,687,953,687	21,554,336,068
+ Undeductible expenses	24,687,953,687	21,554,336,068
- Adjustments to decrease accounting profit to determine taxable income	(9,908,749,904)	-
+ Gain from Joint venture, associated company	(9,908,749,904)	-
- Total taxable income	139,562,627,545	117,447,661,356
- Tax rate	20%	20%
- Current corporate income tax	27,912,525,508	23,489,532,271
- Adjustments of corporate income tax of prior years to that of current year	87,196,915	
- Total current corporate income tax	27,999,722,423	23,489,532,271

	From Jan. 01, 2017 to Sept. 30, 2017	From Jan. 01, 2016 to Sept. 30, 2016
12. Costs of production and doing business by factors		
Raw materials	320,863,871,435	283,246,589,842
Labour cost	80,868,962,605	71,547,225,902
Depreciation and amortization	10,263,490,763	10,673,270,296
Services bought	31,318,865,273	28,289,316,812
Other sundry cash expense	43,327,579,982	44,360,061,493
Total	486,642,770,058	438,116,464,345

	From Jan. 01, 2017 to Sept. 30, 2017	From Jan. 01, 2016 to Sept. 30, 2016
13. Earnings per share		
Accounting profit after corporate income tax	96,783,701,339	72,403,793,017
Profit or loss attributable to ordinary equity holders	96,783,701,339	72,403,793,017
Average ordinary shares outstanding during the year	19,143,167	15,092,434
Earnings per share	5,056	4,797

VII. OTHER INFORMATION

Related party transactions


Related parties	Relationship	Transactions	Movement	Value
An Sinh Hospital	Associate	Sale of goods	Opening balance	625,569,478
			Sale of goods	7,552,048,617
			Proceeds	7,390,799,586
			Closing balance	786,818,509

Prepared By



Le Thi Thu Huong

Chief Accountant



Le Thi Thuy Hang



Huynh Thi Lan

**MEKOPHAR Chemical Pharmaceutical Joint Stock Company**

Addr: 297/5 Ly Thuong Kiet st, Dist 11, Ho Chi Minh City, VietNam

Tel: [028] 38650 258 - 38650 363

Fax: [028] 38650 394

Email: info@mekophar.com

website: www.mekophar.com

Form B 09 - DN**NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS****For the accounting period from Jan. 01, 2017 to Sept. 30, 2017***Unit: VND***V.7. Tangible fixed assets**

Items	Buildings & Structures	Machinery & Equipment	Transportation & Facilities	Others	Total
Original cost					
Opening balance	53,610,571,336	123,343,172,425	15,143,538,903	46,741,190,153	238,838,472,817
<i>New purchase</i>	<i>0</i>	<i>804,375,000</i>	<i>1,316,413,182</i>	<i>278,329,955</i>	<i>2,399,118,137</i>
<i>Disposal, sale</i>			<i>141,797,852</i>		<i>141,797,852</i>
Closing balance	53,610,571,336	124,147,547,425	16,318,154,233	47,019,520,108	241,095,793,102
Accumulated depreciation					
Opening balance	32,104,879,657	94,374,658,718	11,854,428,938	37,344,656,099	175,678,623,412
<i>Charge for the period</i>	<i>1,837,323,808</i>	<i>5,045,720,712</i>	<i>658,204,043</i>	<i>2,705,575,535</i>	<i>10,246,824,098</i>
<i>Disposal, sale</i>			<i>141,797,852</i>		<i>141,797,852</i>
Closing balance	33,942,203,465	99,420,379,430	12,370,835,129	40,050,231,634	185,783,649,658
Net book value					
As at beginning of the period	21,505,691,679	28,968,513,707	3,289,109,965	9,396,534,054	63,159,849,405
As at the end of the period	19,668,367,871	24,727,167,995	3,947,319,104	6,969,288,474	55,312,143,444

**MEKOPHAR Chemical Pharmaceutical Joint Stock Company**

Addr: 297/5 Ly Thuong Kiet st, Dist 11, Ho Chi Minh City, VietNam

Tel: [028] 38650 258 - 38650 363

Fax: [028] 38650 394

Email: info@mekophar.com - website: www.mekophar.com

Form B 09 - DN**NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS****For the accounting period from Jan. 01, 2017 to Sept. 30, 2017***Unit: VND***V.17. Owner's Equity****a. Comparison schedule for changes in Owner's Equity**

Items	Paid-in Capital	Share Premium	Treasury Share	Investment and Development	Undistributed Earnings	Total
Prior year opening balance	151,234,130,000	156,129,704,458	(14,487,151,158)	403,510,093,275	-	696,386,776,575
Profit of year 2016					119,658,840,608	119,658,840,608
Increase capital by issuing stocks	42,974,000,000	138,928,800,000				181,902,800,000
Dividends paid to shareholders in 2016					(19,143,167,000)	(19,143,167,000)
Prior year closing balance	194,208,130,000	295,058,504,458	(14,487,151,158)	403,510,093,275	100,515,673,608	978,805,250,183
Current year opening balance	194,208,130,000	295,058,504,458	(14,487,151,158)	403,510,093,275	100,515,673,608	978,805,250,183
Profit of current period					96,783,701,339	96,783,701,339
Gain/losses from Joint venture, associated company in 2016					(15,469,734,629)	(15,469,734,629)
Management not holding direct management in 2016					(330,000,000)	(330,000,000)
Bonus for the Board of Management in 2016					(1,342,000,000)	(1,342,000,000)
Appropriation to funds from profit of 2016				44,572,965,459	(44,572,965,459)	-
Appropriation to bonus and welfare fund from profit of 2016					(9,844,694,396)	(9,844,694,396)
Dividends paid to shareholders from profit of 2016					(24,886,117,100)	(24,886,117,100)
Other expenses (Mekophar Co.,Ltd.)					(20,000,000)	(20,000,000)
Current period closing balance	194,208,130,000	295,058,504,458	(14,487,151,158)	448,083,058,734	100,833,863,363	1,023,696,405,397